Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As Pharma Looks Beyond The Molecule For Innovation, Can VCs Take Advantage?

This article was originally published in Start Up

Executive Summary

Big Pharma’s growing interest in innovation beyond the molecule that improves health outcomes could provide new opportunities for biotechs and their venture capital backers, but in many areas investors have approached cautiously.

You may also be interested in...

Civitas’ Inhaled L-Dopa Candidate To Start Phase 1, Backed by Michael J. Fox Foundation Grant

Parkinson’s disease is crowded, but Civitas’ value proposition is attractive because the unmet need remains high, the technology shows promise, the clinical trials are straightforward and relatively rapid, and the company, a spinout of Alkermes, starts with clinically validated assets and infrastructure.

Good News, Bad News On Medication Adherence: Problem Understood, Now How To Fix Human Behavior?

The Centers for Medicare and Medicaid Services’ long awaited final rules on Accountable Care Organizations, issued on Oct. 20, include encouraging incentives for medication adherence. That’s good news for the industry, but it also throws a spotlight on the imperfect state of medication adherence methodologies.

Biopharmaceuticals Beyond The Drug: Changing Pharma's Value Proposition

Responding to a convergence of a changing market and shifts in technology, pharmaceutical companies are exploring ways to enhance the value of their products and find new opportunities beyond their core molecule-driven businesses.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts